NCT05642507已完成1 期
Randomized, Double-blind, Multiple Ascending Dose, Placebo-controlled, Safety, Tolerability, Efficacy, Pharmacokinetic (PK) and Pharmacodynamic (PD) Phase Ib/IIa Clinical Trial With AC01 in Patients With HFrEF
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- AnaCardio AB
- 入组人数
- 58
- 试验地点
- 27
- 主要终点
- Safety and tolerability: Adverse Events (AEs)
研究概览
简要总结
This is a randomized, double-blind, placebo-controlled two-part study with a multiple escalating dose phase followed by a cohort expansion phase to assess safety, tolerability, pharmacokinetics and pharmacodynamics of AC01 in patients with heart failure with reduced ejection fraction (HFrEF).
详细描述
During the dose escalation phase, patients were given AC01 orally twice daily for seven days. In the cohort expansion phase, patients were given AC01 orally twice daily for 28 days at dose levels selected on the basis of results of the dose escalation phase.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •, Dose Escalation Phase:
- •Male and female out-patients of any ethnicity, between 18-80 years (inclusive), with stable HFrEF.
- •Chronic HF for at least 6 months duration defined by history with current NYHA class II-III severity.
- •LVEF ≤40% by TTE more than 6 months before screening and again at screening (screening measurement confirmed by echocardiography core lab).
- •Sinus rhythm with mean resting heart rate 55-90 bpm.
- •Cardiac Index 0.5-2.4 measured by Innocor at screening and Day -
- •Screening measurement confirmed by core lab.
- •Transvenous ICD for primary prevention in place and active (as long as it is not subcutaneous).
- •Optimal guideline-based medical therapy for HFrEF as judged by the Investigator, at stable doses for ≥2 weeks with no intention to change dosing during trial duration.
排除标准
- •, Dose Escalation Phase:
- •Any cardiac rhythm that does or could interfere with ECG or TTE interpretation, including but not limited to permanent or persistent atrial fibrillation or flutter or paroxysmal atrial fibrillation or flutter with an episode in the last 3 months, frequent premature ventricular contractions, or atrial or ventricular pacing
- •Ongoing or planned mechanical circulatory support, treatment with any IV vasoactive drugs (vasodilators, inotropes, or vasopressors) or diuretics, and/or dialysis or hemofiltration or ultrafiltration.
- •Probable alternative explanations for symptoms or signs (e.g., but not limited to, known primary cardiomyopathy [hypertrophic, constrictive, restrictive, infiltrative, congenital]). Primary uncorrected hemodynamically significant valve disease, right-sided HF not due to left-sided HF.
- •History of aborted cardiac arrest (cardiac arrest in the setting of myocardial infarction is allowed).
- •Hospitalized for HF or received IV diuretics, vasodilators, or inotropes for HF ≤30 days.
- •Clinical diagnosis of acute coronary syndrome or stroke ≤30 days.
- •PCI or percutaneous valve intervention ≤30 days or planned.
- •Angina pectoris ≤30 days.
- •Any cardiovascular procedure planned during study duration.
- •Hospitalized or unplanned visit to the emergency department for any reason in last 30 days; patient is eligible 30 days from discharge from hospital.
- •Use of any drugs or substances known to be strong inducers of CYP3A4 enzyme within 28 days prior to the first dose of study drug and/or planned to be used during the overall study period until the day after the final dose of study drug (e.g., rifampin, phenytoin).
- •eGFR by CKD-EPI <30 mL/min/1.73 m2 at screening or at Day -
- •Serum or plasma potassium <3.5 or >5.2 mEq/L at screening or at Day -
- •Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 times upper limit of normal (ULN) or total bilirubin >2 times ULN at screening or at Day -1 or known cirrhosis or severe liver or pancreatic disease, or Gilbert's syndrome.
- •Any condition that in the opinion of the Investigator may interfere with adherence to, or makes patient not suitable for, entry into the study.
- •Mean systolic blood pressure <90 mmHg or >140 mmHg, sitting after at least 5 minutes rest at screening or at Day -
- •Any of the following ECG findings at screening or at Day -1: atrial or ventricular pacing, QTcF >450 ms for males and >470 ms for females, AV block I with PQ >240 ms, AV block II or III. In the case of non-paced QRS prolongation >120 ms, the QTcF is allowed to be up to but not greater than 470 ms.
- •Key Inclusion Criteria, Cohort Expansion Phase:
- •Male and female out-patients of any ethnicity, between 18-80 years (inclusive), with stable HFrEF.
- •Chronic HF for at least 6 months duration defined by history with current NYHA class II-III severity.
- •LVEF ≤40% by TTE more than 6 months before screening and again at screening (screening measurement confirmed by echocardiography core lab).
- •Sinus rhythm or permanent, persistent or paroxysmal AFF (AFF at screening capped at ≥25% of enrolled patients) with mean resting heart rate 55-90 bpm measured as part of vital signs, at screening and on Day -
- •Mean defined as mean of 3 separate measurements 1 minute apart.
- •Transvenous ICD for primary prevention in place and active (i.e., subcutaneous ICD not accepted).
- •Optimal guideline-based medical therapy for HFrEF as judged by the Investigator, at stable doses for ≥2 weeks with no intention to change dosing during trial duration.
- •Key Exclusion Criteria, Cohort Expansion Phase:
- •Any cardiac rhythm other than AFF that does or could interfere with ECG or TTE interpretation, including but not limited to >20% of ventricular contractions on ECG strips being premature ventricular contractions including doublets, triplets, bigeminy or trigeminy, or atrial or ventricular pacing.
- •Ongoing or planned mechanical circulatory support, treatment with any IV vasoactive drugs (vasodilators, inotropes, or vasopressors) or diuretics, and/or dialysis or hemofiltration or ultrafiltration.
- •Probable alternative explanations for symptoms or signs (e.g., but not limited to, known primary cardiomyopathy [hypertrophic, constrictive, restrictive, infiltrative, congenital]). Primary uncorrected hemodynamically significant valve disease, right-sided HF not due to left-sided HF.
- •History of aborted cardiac arrest (cardiac arrest in the setting of myocardial infarction is allowed).
- •Hospitalized for HF or received IV diuretics, vasodilators, or inotropes for HF ≤30 days.
- •Clinical diagnosis of acute coronary syndrome or stroke ≤30 days.
- •PCI or percutaneous valve intervention ≤30 days or planned.
- •Angina pectoris ≤30 days.
- •Any cardiovascular procedure planned during study duration.
- •Hospitalized for cardiovascular or other disease in last 30 days as per Investigator discretion; patient is eligible 30 days from discharge from hospital.
- •Use of any drugs or substances known to be strong inducers of CYP3A4 enzyme within 28 days prior to the first dose of study drug and/or planned to be used during the overall study period until the day after the final dose of study drug (e.g., rifampin, phenytoin).
- •eGFR by CKD-EPI <30 mL/min/1.73 m2 at screening.
- •Serum or plasma potassium >5.2 mEq/L at screening. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 times upper limit of normal (ULN) or total bilirubin >2 times ULN at screening or at Day -1 or known cirrhosis or severe liver or pancreatic disease, or Gilbert's syndrome.
- •Any condition that in the opinion of the Investigator may interfere with adherence to, or makes patient not suitable for, entry into the study.
- •Mean systolic blood pressure <90 mmHg or >140 mmHg, sitting after at least 5 minutes rest at screening or at Day -
- •Any of the following ECG findings at screening or at Day -1: atrial or ventricular pacing, QTcF >450 ms for males and >470 ms for females, AV block I with PQ >240 ms, AV block II or III. In the case of non-paced QRS prolongation >120 ms, the QTcF is allowed to be up to but not greater than 470 ms.
结局指标
主要结局
Safety and tolerability: Adverse Events (AEs)
时间窗: Up to 12 days during dose escalation phase and up to 35 days during cohort expansion phase.
Type and frequency of AEs.
Safety and tolerability: Vital signs.
时间窗: Up to 12 days during dose escalation phase and up to 35 days during cohort expansion phase.
Systolic and diastolic blood pressure.
Safety and tolerability: Electrocardiogram (ECG).
时间窗: Up to 12 days during dose escalation phase and up to 35 days during cohort expansion phase.
Number of clinically significant abnormal findings values of RR-, PR-, QRS- QTc intervals.
Safety and tolerability: Clinical laboratory evaluations.
时间窗: Up to 12 days during dose escalation phase and up to 35 days during cohort expansion phase.
Number of clinically significant laboratory abnormalities
次要结局
- Pharmacokinetics of AC01 and its major metabolite: Cmax.(Up to Day 8 during dose escalation phase and up to Day 32 during cohort expansion phase.)
- Pharmacodynamics: Mechanistic markers.(Up to 12 days during dose escalation phase and up to 35 days during cohort expansion phase.)
- Pharmacokinetics of AC01 and its major metabolite: AUC(Up to Day 8 during dose escalation phase and up to Day 32 during cohort expansion phase.)
- Pharmacodynamics: Cardiac Function.(Up to 12 days during dose escalation phase and up to 35 days during cohort expansion phase.)
研究者
研究点 (27)
Loading locations...
相似试验
已完成
1 期
A Study of the Cardiac Effects of ALXN2050 in Healthy AdultsHealthyNCT04660890Alexion Pharmaceuticals, Inc.39
已完成
1 期
AT-301 Nasal Spray in Healthy AdultsHealthyNCT04519788Atossa Therapeutics, Inc.32
已完成
1 期
A First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of QCC374Healthy SubjectsNCT02245828Novartis Pharmaceuticals66
已完成
1 期
Multiple-dose Escalation Clinical Study of VC005 Tablets in Healthy SubjectsInflammatory Bowel DiseasesNCT05354752Jiangsu vcare pharmaceutical technology co., LTD60
已完成
1 期
AZD8108 SAD/MAD in Healthy VolunteersHealthy VolunteersNCT02248818AstraZeneca258